A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
COVID-19 caused by SARS-CoV-2 has become a global pandemic requiring the development of interventions for the prevention or treatment to curtail mortality and morbidity. No vaccine to boost mucosal immunity, or as a therapeutic, has yet been developed to SARS-CoV-2. In this study, we discover and ch...
Main Authors: | Ejemel, M, Li, Q, Hou, S, Schiller, ZA, Tree, JA, Wallace, A, Amcheslavsky, A, Kurt Yilmaz, N, Buttigieg, KR, Elmore, MJ, Godwin, K, Coombes, N, Toomey, JR, Schneider, R, Ramchetty, AS, Close, BJ, Chen, D-Y, Conway, HL, Saeed, M, Ganesa, C, Carroll, MW, Cavacini, LA, Klempner, MS, Schiffer, CA, Wang, Y |
---|---|
Format: | Journal article |
Language: | English |
Published: |
Springer Nature
2020
|
Similar Items
-
A cross-reactive human IgA monoclonal antibody blocks SARS-CoV-2 spike-ACE2 interaction
by: Monir Ejemel, et al.
Published: (2020-08-01) -
Mucosal nanobody IgA as inhalable and affordable prophylactic and therapeutic treatment against SARS-CoV-2 and emerging variants
by: Qi Li, et al.
Published: (2022-09-01) -
Investigation of a monoclonal antibody against enterotoxigenic Escherichia coli, expressed as secretory IgA1 and IgA2 in plants
by: Audrey Y-H Teh, et al.
Published: (2021-01-01) -
Anti-CfaE nanobodies provide broad cross-protection against major pathogenic enterotoxigenic Escherichia coli strains, with implications for vaccine design
by: Alla Amcheslavsky, et al.
Published: (2021-02-01) -
Impact of IgA constant domain on HIV-1 neutralizing function of monoclonal antibody F425-A1g8
by: Yu X, et al.
Published: (2012-09-01)